TABLE 1.

Clinicopathologic features of patients undergoing extensive cytoreductive surgery

	Comparison group (n = 222)	Extensive CRS (n = 60)	p value
Age years, mean ± SD	54.7 ± 11.8	55.5 ± 10.3	0.6
Gender			0.9
Male	110 (49.5 %)	29 (48.3 %)
Female	112 (50.5 %)	31 (51.7 %)
BMI, mean ± SD	27.1 ± 5.1	28.0 ± 7.5	0.3
ASA			0.2
1 (n = 2)	1 (0.7 %)	1 (2.1 %)
2 (n = 35)	30 (21.3 %)	5 (10.4 %)
3 (n = 134)	88 (62.4 %)	36 (75.0 %)
4 (n = 28)	22 (15.6 %)	6 (12.5 %)
Preoperative serum  albumin (g/dL)	3.7 ± 0.8	3.5 ± 0.8	0.2
Primary vs recurrence			0.9
Primary (n = 134)	104 (49.1 %)	30 (50.8 %)
Recurrence (n = 137)	108 (50.9 %)	29 (49.2 %)
Symptomatic	129 (58.1 %)	46 (76.7 %)	0.01
Prior chemotherapy	89 (40.1 %)	20 (33.3 %)	0.4
Prior HIPEC	17 (7.8 %)	4 (6.8 %)	1.0
CT-evident disease	136 (61.5 %)	45 (75.0 %)	0.07
CT-evident mass	59 (26.8 %)	34 (56.7 %)	0.0001
Duration, minutes,  median (IQR)	460 (390–750)	555 (460–660)	0.0004
Estimated blood loss,  mL, median (IQR)	750 (400–2,500)	1,225 (750– 2,050)	0.0006
Units RBCs transfused			0.007
0 (n = 73)	64 (37.0 %)	9 (17.3 %)
1–2 (n = 56)	42 (24.3 %)	14 (26.9 %)
>3 (n = 96)	67 (38.7 %)	29 (55.8 %)
SPCI, median (IQR)	13 (8–16)	16 (14–18)	<0.0001
Complete cytoreduction  (CC-0/1)	185 (84.5 %)	45 (75.0 %)	0.1
HIPEC performed	198 (93.4 %)	53 (88.3 %)	0.8
Histologic grade			1.0
Low grade (n = 180)	141 (64.1 %)	39 (65.0 %)
High grade (n = 100)	79 (35.9 %)	21 (35.0 %)
Signet ring cells			0.8
Not present (n = 245)	192 (86.5 %)	53 (88.3 %)
Present (n = 37)	30 (13.5 %)	7 (11.7 %)
Positive lymph nodes			0.4
Not identified  (n = 154)	121 (78.1 %)	33 (71.7 %)
Identified (n = 47)	34 (21.9 %)	13 (28.3 %)

SD standard deviation, IQR interquartile range